Hepatic steatosis in people older and younger than fifty who are living with HIV and HIV-negative controls: A cross-sectional study nested within the POPPY cohort.
HIV
hepatic steatosis
liver disease
obesity
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
received:
23
05
2023
accepted:
16
08
2023
medline:
6
9
2023
pubmed:
6
9
2023
entrez:
5
9
2023
Statut:
aheadofprint
Résumé
Hepatic steatosis is a major cause of chronic liver disease associated with several negative health outcomes. We compared the prevalence of and factors associated with steatosis in people living with and without HIV. Older (>50 years) and younger (<50 years) people with HIV and older HIV-negative controls (>50 years) underwent liver transient elastography examination with controlled attenuation parameter (steatosis ≥238 dB/m, moderate/severe steatosis ≥280 dB/m, liver fibrosis ≥7.1 kPa). We compared groups using logistic regression/Chi-squared/Fisher's exact/Kruskal-Wallis tests. In total, 317 participants (109 older people with HIV; 101 younger people with HIV; 107 HIV-negative controls) were predominantly white (86%) and male (76%), and 21% were living with obesity (body mass index ≥30 kg/m The prevalence of hepatic steatosis and fibrosis was similar between older participants regardless of HIV status. Age, sex, and abdominal obesity, but not HIV-related variables, were associated with steatosis. Interventions for controlling obesity should be integrated into routine HIV care.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatic steatosis is a major cause of chronic liver disease associated with several negative health outcomes. We compared the prevalence of and factors associated with steatosis in people living with and without HIV.
METHODS
METHODS
Older (>50 years) and younger (<50 years) people with HIV and older HIV-negative controls (>50 years) underwent liver transient elastography examination with controlled attenuation parameter (steatosis ≥238 dB/m, moderate/severe steatosis ≥280 dB/m, liver fibrosis ≥7.1 kPa). We compared groups using logistic regression/Chi-squared/Fisher's exact/Kruskal-Wallis tests.
RESULTS
RESULTS
In total, 317 participants (109 older people with HIV; 101 younger people with HIV; 107 HIV-negative controls) were predominantly white (86%) and male (76%), and 21% were living with obesity (body mass index ≥30 kg/m
CONCLUSIONS
CONCLUSIONS
The prevalence of hepatic steatosis and fibrosis was similar between older participants regardless of HIV status. Age, sex, and abdominal obesity, but not HIV-related variables, were associated with steatosis. Interventions for controlling obesity should be integrated into routine HIV care.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : ViiV Healthcare
Informations de copyright
© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78.
Seth A, Sherman KE. Fatty liver disease in persons with HIV infection. Top Antivir Med. 2019;27(2):75-82.
Tafesh ZH, Verna EC. Managing nonalcoholic fatty liver disease in patients living with HIV. Curr Opin Infect Dis. 2017;30(1):12-20.
Gervasoni C, Cattaneo D, Filice C, Galli M, Nimi GIS. Drug-induced liver steatosis in patients with HIV infection. Pharmacol Res. 2019;145:104267.
Nabi O, Lacombe K, Boursier J, Mathurin P, Zins M, Serfaty L. Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO study. Gastroenterology. 2020;159(2):791-3 e2.
Bagkeris E, Burgess L, Mallon PW, et al. Cohort profile: the pharmacokinetic and clinical observations in PeoPle over fiftY (POPPY) study. Int J Epidemiol. 2018;47(5):1391-2e.
Savinelli S, De Francesco D, Feeney ER, et al. Factors associated with obesity in the pharmacokinetic and clinical observations in people over fifty (POPPY) cohort: an observational cross-sectional analysis. HIV Med. 2020;21(7):441-452.
Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG, World Health Organization. In: Organization WH, ed. AUDIT: the Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care. 2nd Edition ed. World Health Organization; 2001.
Berman AHBH, Palmstierna T, Schlyter F. In: Institutet K, ed. DUDIT the Drug Use Disorders Identification Test Manual. Karolinska Institutet; 2003.
Vuille-Lessard E, Lebouche B, Lennox L, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. Aids. 2016;30(17):2635-2643.
Price JC, Seaberg EC, Badri S, Witt MD, D'Acunto K, Thio CL. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis. 2012;205(6):1005-1013.
Mendeni M, Foca E, Gotti D, et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis. 2011;52(9):1164-1173.
Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013;59(2):236-242.
Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137(3):865-872.
Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503-508.
Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362-373.
Nordholt ES. Imputation: methods, simulation experiments and practical examples. Int Stat Rev. 1998;66(2):157-180.
Kuang M, Lu S, Xie Q, et al. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population. BMC Gastroenterol. 2022;22(1):311.
Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the multicenter AIDS cohort study. Am J Gastroenterol. 2014;109(5):695-704.
Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47(2):250-257.
Cervo A, Milic J, Mazzola G, et al. Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus. Clin Infect Dis. 2020;71(10):e694-e701.
Michel M, Labenz C, Wahl A, et al. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV. Aids. 2022;36(12):1665-1674.
Krahn T, Martel M, Sapir-Pichhadze R, et al. Nonalcoholic fatty liver disease and the development of metabolic comorbid conditions in patients with human immunodeficiency virus infection. J Infect Dis. 2020;222(5):787-797.
Hagstrom H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018;2(1):48-57.
Kirkegaard-Klitbo DM, Thomsen MT, Gelpi M, Bendtsen F, Nielsen SD, Benfield T. Hepatic steatosis associated with exposure to Elvitegravir and Raltegravir. Clin Infect Dis. 2021;73(3):e811-e814.
Benedicto AM, Fuster-Martinez I, Tosca J, Esplugues JV, Blas-Garcia A, Apostolova N. NNRTI and liver damage: evidence of their association and the mechanisms involved. Cell. 2021;10(7):1687.
Bischoff J, Gu W, Schwarze-Zander C, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine. 2021;40:101116.
Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54(4):773-794.
Burns JE, Stirrup OT, Dunn D, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. Aids. 2020;34(1):109-114.
Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471-e477.
Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484.
Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379-1389.
Vali Y, Lee J, Boursier J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020;73(2):252-262.
Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020;69(7):1343-1352.
Fourman LT, Lu MT, Lee H, et al. Differential relationships of hepatic and epicardial fat to body composition in HIV. Physiol Rep. 2017;5(19):e13386.
Ajmera VH, Cachay ER, Ramers CB, et al. Optimal threshold of controlled attenuation parameter for detection of HIV-associated NAFLD with magnetic resonance imaging as the reference standard. Clin Infect Dis. 2021;72(12):2124-2131.